| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Articles |
-Dihydrotestosterone during Development of the Male Urogenital Tract1
Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas 75235-8857
Address all correspondence and requests for reprints to: F. W. George, Ph.D., Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235-8857. E-mail: george02{at}utsw.swmed.edu
Previous work has clearly demonstrated that inhibition of
5
-dihydrotestosterone (DHT) formation in vivo is not
as effective as total androgen ablation (castration) in causing
involution of the prostate. It is likely that this is due to the fact
that testosterone is partially effective in maintaining androgen
action. To provide insight into this observation, the androgenic
metabolites of testosterone, androstenedione, and 5
-DHT, were
measured in prostate tissue and in blood of 5
-reductase inhibitor
(finasteride)-treated adult male rats. Finasteride treatment caused a
significant decrease in prostatic DHT levels and a profound increase in
prostatic testosterone and androstenedione levels. Similarly,
circulating DHT levels were decreased in finasteride-treated rats (0.02
ng/ml compared with 0.05 ng/ml seen in control rats), and circulating
androstenedione and testosterone levels were significantly elevated in
finasteride-treated animals compared with controls. The in
vitro effects of finasteride were assessed on the metabolism of
[3H]testosterone in a tissue-slice assays. In the
prostate, the inhibition of 5
-reductase activity resulted not only
in the decreased formation of 5
-reduced metabolites (primarily DHT
and 5
-androstanedione), but also an increase in the 17-oxo
metabolite androstenedione. In contrast, the tissues derived from the
embryonic wolffian duct (seminal vesicle and epididymis) formed
relatively low amounts of 17-keto steroids. Because DHT is a high
affinity ligand for the androgen receptor and androstenedione shows
very little, if any, affinity for the receptor, these studies suggest
that 5
-reduction of testosterone may be a mechanism to amplify
androgen action in urogenital tissues such as the prostate by
preventing catabolism of testosterone to the inactive androgen,
androstenedione, at the site of hormone action.
This article has been cited by other articles:
![]() |
L. K. Potter, M. G. Zager, and H. A. Barton Mathematical model for the androgenic regulation of the prostate in intact and castrated adult male rats Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E952 - E964. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Borst, J. H. Lee, and C. F. Conover Inhibition of 5{alpha}-reductase blocks prostate effects of testosterone without blocking anabolic effects Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E222 - E227. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow, D. D. Miller, and J. T. Dalton Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5{alpha}-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia Endocrinology, December 1, 2004; 145(12): 5420 - 5428. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. McIntyre, N. J. Barlow, and P. M. D. Foster Androgen-Mediated Development in Male Rat Offspring Exposed to Flutamide in Utero: Permanence and Correlation of Early Postnatal Changes in Anogenital Distance and Nipple Retention with Malformations in Androgen-Dependent Tissues Toxicol. Sci., August 1, 2001; 62(2): 236 - 249. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ohsako, Y. Miyabara, N. Nishimura, S. Kurosawa, M. Sakaue, R. Ishimura, M. Sato, K. Takeda, Y. Aoki, H. Sone, et al. Maternal Exposure to a Low Dose of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) Suppressed the Development of Reproductive Organs of Male Rats: Dose-Dependent Increase of mRNA Levels of 5{{alpha}}-Reductase Type 2 in Contrast to Decrease of Androgen Receptor in the Pubertal Ventral Prostate Toxicol. Sci., March 1, 2001; 60(1): 132 - 143. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Sperry and P. Thomas Characterization of Two Nuclear Androgen Receptors in Atlantic Croaker: Comparison of Their Biochemical Properties and Binding Specificities Endocrinology, April 1, 1999; 140(4): 1602 - 1611. [Abstract] [Full Text] |
||||
![]() |
V. A. Tobin and B. J. Canny The Regulation of Gonadotropin-Releasing Hormone-Induced Calcium Signals in Male Rat Gonadotrophs by Testosterone Is Mediated by Dihydrotestosterone Endocrinology, March 1, 1998; 139(3): 1038 - 1045. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |